51 completed, 1 active not recruiting, 1 not yet recruiting, 1 terminated. 55 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 55 | Completed 51, Active not recruiting 1, Not yet recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Haemophilus Influenzae Type b: new trials by email Literature Review of Haemophilus Influenzae Type b trials Research Report on Haemophilus Influenzae Type b
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of BK1803 in Healthy Infants BK1803, GOBIK Aqueous Suspension Syringes, Bimmugen® Injection - Pertussis, Diphtheria | Phase 3 | Not yet recruiting | Tanabe Pharma Corporation | 344 | 2026-10-01 | 2026-08-28 |
| A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series LBVD, Pentavalent vaccine and Inactivated Polio vaccine - Diphtheria, Tetanus | Phase 2 / Phase 3 | Active not recruiting | LG Chem | 1186 | 2025-05-30 | 2026-09-03 |
| Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants Infanrix-IPV/Hib - Diphtheria, Acellular Pertussis | Phase 3 | Withdrawn | GlaxoSmithKline | 2017-12-01 | 2017-12-26 | |
| A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia Infanrix-IPV/Hib - Diphtheria, Tetanus | Phase 3 | Completed | GlaxoSmithKline | 235 | 2016-09-13 | 2019-09-24 |
| Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth Hexaxim® - Diphtheria, Tetanus | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 354 | 2015-04-20 | 2022-04-05 |
| Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants Infanrix hexa, Pediarix, ActHIB - Poliomyelitis, Diphtheria | Phase 3 | Completed | GlaxoSmithKline | 585 | 2014-04-16 | 2019-11-27 |
| Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age Hib-MenCY-TT (MenHibrix®), Pediarix®, Rotarix® - Neisseria Meningitidis, Haemophilus Influenzae Type b | Phase 3 | Completed | GlaxoSmithKline | 600 | 2014-02-01 | 2018-09-14 |
| Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination DTaP-IPV-Hep B- PRP~T + Prevenar + Rotarix vaccine, DTaP- IPV-Hep B-PRP~T + Prevenar + Rotarix + Infanrix hexa vaccine, Infanrix hexa + Prevenar + Rotarix vaccine - Diphtheria, Tetanus | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 558 | 2013-10-01 | 2016-01-05 |
| Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers Infanrix-IPV+Hib™ - Acellular Pertussis, Haemophilus Influenzae Type b | Phase 3 | Completed | GlaxoSmithKline | 321 | 2012-12-08 | 2020-01-21 |
| Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine Infanrix hexa™ - Poliomyelitis, Tetanus | Phase 3 | Completed | GlaxoSmithKline | 224 | 2012-04-16 | 2020-01-02 |
| Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine Infanrix+Hib™, Poliorix™ - Acellular Pertussis, Tetanus | Phase 3 | Completed | GlaxoSmithKline | 831 | 2011-10-01 | 2018-06-06 |
| Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine Infanrix™-IPV+Hib, Infanrix™ IPV, Hiberix™ - Poliomyelitis, Tetanus | Phase 3 | Completed | GlaxoSmithKline | 454 | 2011-03-04 | 2019-11-27 |
| Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants. PENTAXIM™: DTacP IPV//PRP~T combined vaccine, TETRAXIM™: DTacP IPV combined vaccine and ActHIB™: PRP tetanus conjugate vaccine - Diphtheria, Tetanus | Phase 3 | Completed | Sanofi | 370 | 2010-09-01 | 2012-04-17 |
| Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108), ActHIB™, Pentacel™ - Haemophilus Influenzae Type b | Phase 3 | Completed | GlaxoSmithKline | 4003 | 2010-06-18 | 2018-07-12 |
| Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine Infanrix-IPV/Hib™, Infanrix Hib™, Poliorix™ - Tetanus, Poliomyelitis | Phase 3 | Completed | GlaxoSmithKline | 985 | 2010-03-01 | 2018-06-06 |
| A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy Infants DTaP//PRP-T Combined Vaccine, DTaP Combined Vaccine and PRP-Tetanus Conjugate Vaccine - Diphtheria, Tetanus | Phase 3 | Completed | Sanofi | 1056 | 2010-01-01 | 2011-12-13 |
| Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib) Infanrix™-IPV/Hib - Haemophilus Influenzae Type b, Acellular Pertussis | Phase 3 | Completed | GlaxoSmithKline | 50 | 2009-12-01 | 2018-06-06 |
| Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines MenitorixTM, Pneumococcal conjugate vaccine GSK1024850A, PrevenarTM - Neisseria Meningitidis, Haemophilus Influenzae Type b | Phase 3 | Completed | GlaxoSmithKline | 582 | 2009-05-14 | 2018-02-15 |
| Safety and Immunogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b Haemophilus influenzae type b vaccine, Commercial Haemophilus influenzae type b vaccine - Haemophilus Influenzae Type b | Phase 3 | Completed | Novartis Vaccines | 916 | 2008-11-01 | 2011-12-29 |
| Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants DTaP IPV HB PRP~T vaccine, DTaP-HB-IPV and Haemophilus influenzae type b - Diphtheria, Tetanus | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 263 | 2008-05-01 | 2016-05-13 |
Showing 20 of 55. Sign in to see all of them.
Haemophilus Infections (55) · Diphtheria (39) · Tetanus (37) · Hepatitis B (26) · Poliomyelitis (23) · Whooping Cough (19) · Gram-Negative Bacterial Infections (1) · Influenza, Human (1) · Meningococcal Infections (1) · Pneumococcal Infections (1)
Bacterial Infections (55) · Bacterial Infections and Mycoses (55) · Infections (55) · Pasteurellaceae Infections (55) · Gram-Negative Bacterial Infections (54) · Actinomycetales Infections (39) · Corynebacterium Infections (39) · Gram-Positive Bacterial Infections (39) · Clostridium Infections (37) · Virus Diseases (37) · Blood-Borne Infections (26) · Communicable Diseases (26) · DNA Virus Infections (26) · Digestive System Diseases (26) · Hepadnaviridae Infections (26)
diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (11) · Hiberix (8) · Vaccines (7) · Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate (6) · Heptavalent Pneumococcal Conjugate Vaccine (6) · PEDIARIX (5) · RIX4414 vaccine (5) · DTaP-IPV-HB-PRP-T vaccine (4) · Diphtheria-Tetanus-acellular Pertussis Vaccines (4) · Tetanus Toxoid (4) · Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine (3) · Measles-Mumps-Rubella Vaccine (3) · pentacel (3) · 13-valent pneumococcal vaccine (2) · Chickenpox Vaccine (2)
GlaxoSmithKline (38) · Sanofi Pasteur, a Sanofi Company (9) · Sanofi (4) · LG Chem (1) · Merck Sharp & Dohme LLC (1) · Novartis Vaccines (1) · Tanabe Pharma Corporation (1)
United States (8) · China (7) · Philippines (6) · Thailand (6) · Spain (5) · Mexico (4) · India (3) · Poland (3) · Australia (2) · Finland (2) · Peru (2) · South Korea (2) · Vietnam (2) · Argentina (1) · Colombia (1)
PMID 17716936, PMID 22327493, PMID 18463125, PMID 19117896, PMID 20950456, PMID 21219984, PMID 21289531, PMID 21334243, PMID 21807056, PMID 21875633, PMID 22001281, PMID 22531237, PMID 23340564, PMID 23966556, PMID 27145999, PMID 27510380, PMID 31307216, PMID 32048889